Company Analysis
Sign in

LENZ Therapeutics, Inc. (LENZ)

Nasdaq: LENZ · Biological Products, (No Diagnostic Substances) · Solana Beach, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.6
◀ Past 6.5● Present 5.8▶ Future 4.8
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$19.1M
Net income-$82.1M-65.0%
Earnings per share$-2.85-21.8%
Operating cash flow-$69.2M-16.5%
Cash$25.2M+24.9%
Debtn/a
Shareholders’ equity$284M+39.3%
Shares, diluted28.8M+35.4%
Return on equity-28.9%
The recordfrom its filings
Filings in 202643
Newest filingNov 5 · SCHEDULE 13G/A
Annual reportMar 24, 2026
Quarterly reportNov 3, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$9.4M
Insider buys, 12 months$700,000
Patents granted9
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $12.4MNet income -$140MCash from operations -$128Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 28, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 27, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton LENZ · research, not advice